Breaks Categories: News

TuesdayApr 09, 2024 2:20 pm

HempNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Closes on $3.2M Public Offering

Flora Growth (NASDAQ: FLGC), a cannabis-focused consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000-plus points of distribution around the world, has closed on an underwritten public offering. The offering, which was comprised of 1.7 million common shares, resulted in $3.23 million in gross proceeds for Flora Growth, before deductions. Flora Growth plans to use the funds from the offering for general corporate and working capital needs. Aegis Capital Corp. acted as the sole book-running manager for the offering, which closed on April 8, 2024. In addition, the company announced that its CEO, Clifford…

Continue Reading

MondayApr 08, 2024 1:14 pm

HempNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Approved as US Government Vendor, Proprietary TRACER 1000 Listed on GSA

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its wholly owned subsidiary, 1st Detect Corporation, have announced that its TRACER 1000(TM) is now listed in the U.S. General Services Administration (“GSA”) IT Schedule 70, making the company an approved U.S. government vendor. The device can be found under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290. According to the announcement, IT Schedule 70 is a long-term contract issued to commercial technology vendors that allows sales to the U.S. government, one of the largest buyers of goods and services in the world. A high-performance laboratory instrument of ruggedized mass…

Continue Reading

ThursdayApr 04, 2024 2:23 pm

HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting additional preclinical data demonstrating the positive effects of its INM-901 for the potential treatment of Alzheimer's disease ("AD"). Highlights of the report note that INM-901 receptor binding studies indicate preferential signaling agonism for both cannabinoid 1 (“CB1”) and cannabinoid 2 (“CB2”) and impacts the peroxisome proliferator-activated receptors (“PPAR”) signaling pathway while in vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function. In addition, molecular analysis data explains previously reported observations in behavioral studies on locomotion, memory and cognition. According…

Continue Reading

ThursdayApr 04, 2024 1:19 pm

HempNewsBreaks – Golden Triangle Ventures Inc. (GTVH) to Release Series of CEO Interviews through Collaboration with NowMedia Networks

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, is partnering with NowMedia Networks to release a series of weekly interviews with GTVH CEO and president Steffan Dalsgaard. The series is initially planned for 12 weeks with the objective of sharing the company’s story. This partnership allows GTVH to distribute the interviews to more than 34 million televisions through 10-plus networks; these interviews will be targeting investors, business owners and entrepreneurs. NowMedia TV has built a reputation for offering high-quality bilingual and business-oriented content and will integrate the pioneering perspectives of Golden Triangle Ventures into its acclaimed shows “Power CEOs”…

Continue Reading

TuesdayApr 02, 2024 3:55 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives New Epilepsy, Anti-Viral Agent Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received three new patent awards. According to the announcement, the company was awarded two new patents in its epilepsy patent family; both awards were granted in the United States. The U.S. patents, which cover both swallowed capsules and dissolvable oral tablets, complement research indicating DehydraTECH-CBD has potential to decrease epileptic seizures in rodents and to be absorbed into the bloodstream more effectively than the current treatments. In addition, Lexaria was awarded a patent in Japan in is antiviral agent patent family. The new patents bring the total of…

Continue Reading

TuesdayApr 02, 2024 3:10 pm

HempNewsBreaks – Astrotech Corp. (NASDAQ: ASTC), Subsidiary Set to Spotlight Tracer 1000 Trace Detector at Leading Security Trade Event

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its wholly owned subsidiary, 1st Detect Corporation, will be showcasing the TRACER 1000 Narcotics Trace Detector (“NTD”) and Explosives Trace Detector (“ETD”) at the International Security Conference and Exposition. Known as ISC West, the conference and expo is slated to run April 9–12, 2024, in Las Vegas; the event is the one of the leading comprehensive security trade events in the nation and will be attended by key security and public-safety professionals. A high-performance laboratory instrument powered by Astrotech Mass Spectrometer Technology(TM), the TRACER 1000 can detect trace levels of narcotics…

Continue Reading

MondayMar 25, 2024 3:00 pm

HempNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Launches ‘Gold Standard’ of Mass Spectrometry into Narcotics Detection Market

Astrotech (NASDAQ: ASTC) and its wholly owned subsidiary, 1st Detect Corporation, today announced that the company is currently accepting orders for the Tracer 1000 Narcotics Trace Detector (“NTD”). A high-performance laboratory instrument, the TRACER 1000 NTD is capable of rapid detection of trace levels of narcotic compounds in seconds. With the company’s Tracer 1000 Explosive Trace Detector (“ETD”) now found in multiple locations in 14 countries, the NTD provides a ruggedized platform that can be applied across various markets including airports, border security, checkpoint, cargo, and infrastructure security, correctional facilities, military, and law enforcement. “Over the last five years our…

Continue Reading

ThursdayFeb 22, 2024 1:07 pm

HempNewsBreaks – MAISON BLOOM Announces New Owner-Partner as UFC Fighter, Entrepreneur Joins Company

MAISON BLOOM, creators of the world’s first all-natural elevated seltzer made from fully sustainable ingredients, has announced a new owner-partner. Marlon “Chito’ Vera, a well-known UFC fighter and entrepreneur, has joined the company, taking “a leap into the world of infused beverages and functional cannabinoid ready-to-drink beverages” as part of his mission to share his approach to “always-ready-living” with the world. Vera will serve as the company’s head of wellness. With Vera on board, MAISON BLOOM plans to launch the “Chito Challenge,” which will include a series of bold offerings and engagements that encourage people to live their best lives.…

Continue Reading

TuesdayDec 12, 2023 1:55 pm

HempNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Creates New Subsidiary, Announces Application of New Technology

Astrotech (NASDAQ: ASTC), an innovative science and technology company, has formed a new wholly owned subsidiary: Pro-Control Inc. According to the announcement, Pro-Control is unveiling its proprietary Pro-Control Maximum Value Process(TM) (Pro-Control MVP(TM) and the Pro-Control-1000(TM) mass spectrometer. The spectrometer has been designed to work within a chemical factory analyzing real-time samples while achieving optimized yields, quality and profits. It tests, measures and increases potency, purity and weight yields. Astrotech has entered into an exclusive license with Pro-Control to use the ATi mass spectrometer technology for chemical manufacturing process control applications. The Pro-Control MVP rapid test can take up to 20 tests…

Continue Reading

FridayDec 08, 2023 10:56 am

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Update on FDA Application for Investigational Drug

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is planning to submit an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) in the next 45 days. The application is for the company’s planned U.S. phase 1b Hypertension Clinical Trial. The filing had been delayed for necessary documentation from a raw material supplier, which is now being provided, enabling Lexaria to finalize the IND application. According to the announcement, the supplier anticipates providing the final two pieces of outstanding information to the FDA within the next 45 days, after which Lexaria can proceed…

Continue Reading